Surveillance and Active Monitoring Strategies for Cancer: Sometimes Less Is More

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 2552

Special Issue Editors


E-Mail Website
Guest Editor
Division of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Interests: prostate cancer; biostatistics; epidemiology; translational research

E-Mail Website
Guest Editor
Division of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Interests: testicular cancer; penile cancer, prostate cancer; translational research

E-Mail Website
Guest Editor
Division of Urology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Interests: prostate; renal cancer; translational research; genitourinary biomarkers

Special Issue Information

Dear Colleagues,

We are working on a Special Issue for Current Oncology titled “Surveillance and Active Monitoring Strategies for Cancer: Sometimes Less Is More”. We are pleased to invite you to contribute a paper to this Special Issue, considering your expertise in Urologic Oncology. This Special Issue aims to describe the current state of the art and contemporary outcomes of different surveillance and active monitoring strategies for patients with genitourinary cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: prostate cancer, non-muscle-invasive bladder cancer, small renal masses, renal cell carcinoma, small testicular masses, CS I testicular cancer, adrenal neoplasms, etc. We look forward to receiving your contributions.

The aim of this Special Issue is to describe the current state of the art and contemporary outcomes of different surveillance and active monitoring strategies for patients with cancer.

The scope of this Special Issue includes a comprehensive examination of surveillance and active monitoring strategies across various types of cancer, including but not limited to prostate cancer, renal cancer, non-muscle-invasive bladder cancer, small testicular masses, and adrenal incidentalomas.

Furthermore, we aim to explore the different surveillance strategies used in cancer management, such as imaging techniques (e.g., computed tomography, magnetic resonance imaging, ultrasound), biomarker assessments (e.g., blood tests, genetic markers), and clinical evaluation methods (e.g., physical examination, symptom monitoring).

The scope of this issue also involves evaluating the outcomes associated with different surveillance and active monitoring strategies for cancer patients. This includes assessing the effectiveness of these strategies in detecting cancer progression and improving survival rates, enhancing quality of life, and minimizing unnecessary interventions.

Additionally, we aim to understand the perspectives and experiences of cancer patients regarding surveillance and active monitoring strategies. This could involve examining patient satisfaction, preferences, adherence to monitoring protocols, and the impact of these strategies on their overall well-being.

Dr. Rashid K Sayyid
Dr. Julian Chavarriaga
Dr. Rui Bernandino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surveillance
  • watchful waiting
  • active monitoring
  • cancer
  • survival

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

20 pages, 694 KiB  
Systematic Review
Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
by Diego Parrao, Nemecio Lizana, Catalina Saavedra, Matías Larrañaga, Carolina B. Lindsay, Ignacio F. San Francisco and Juan Cristóbal Bravo
Curr. Oncol. 2024, 31(4), 2201-2220; https://doi.org/10.3390/curroncol31040163 - 12 Apr 2024
Cited by 3 | Viewed by 2084
Abstract
Bladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a [...] Read more.
Bladder cancer (BC) is the tenth most common cause of cancer worldwide and is the thirteenth leading cause of cancer mortality. The non-muscle invasive (NMI) variant represents 75% of cases and has a mortality rate of less than 1%; however, it has a high recurrence rate. The gold standard of management is transurethral resection in the case of new lesions. However, this is associated with significant morbidity and costs, so the reduction of these procedures would contribute to reducing complications, morbidity, and the burden to the health system associated with therapy. In this clinical scenario, strategies such as active surveillance have emerged that propose to manage low-risk BC with follow-up; however, due to the low evidence available, this is a strategy that is underutilized by clinicians. On the other hand, in the era of biomarkers, it is increasingly known how to use them as a tool in BC. Therefore, the aim of this review is to provide to clinical practitioners the evidence available to date on AS and the potential role of biomarkers in this therapeutic strategy in patients with low-grade/risk NMIBC. This is the first review linking use of biomarkers and active surveillance, including 29 articles. Full article
Show Figures

Figure 1

Back to TopTop